Back to results
US 2011/0033853 A1Published application
CSNKS As Modifiers of the RAC Pathway and Methods of Use
AssigneeExelixis, Inc.
InventorsLISA C. KADYK, GEORGE ROSS FRANCIS, LYNN MARGARET BJERKE
Life of this patent
Estimating the term…
Abstract
Human CSNK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of CSNK are provided.
Claims11
1-25. (canceled)
A method for diagnosing cancer in a subject comprising:
- (a) obtaining a biological sample from the subject;
- (b) determining the level of expression of Casein Kinase II alpha 1(CSNK2A1) in the biological sample of step (a);
- (c) comparing the level of expression of CSNK2A1 in the biological sample of step
- (b) with the level of expression of CSNK2A1 in a control sample;
- and
- (d) determining an elevated level of CSNK2A1 expression in the biological sample compared with the control sample, wherein said elevated level indicates a likelihood of cancer.
3 more elements
Dependencies are inferred from the claim text.